Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals reported second-quarter 2026 results highlighting progress for its oral ITK inhibitor soquelitinib, now in testing across five diseases. In a Phase 1 atopic dermatitis trial, 75% of patients on 200 milligram twice-daily dosing achieved EASI-75 at 8 weeks versus 20% on placebo, with benefits persisting after dosing stopped. The company plans a roughly 200-patient Phase 2 SEERA-1 trial with enrollment completing in early 2027 and results the following quarter. Corvus ended the quarter with $215 million in cash and marketable securities, up from $56.8 million at the end of 2025, after raising $189 million in a first-quarter follow-on offering, funding operations into the second quarter of 2028. R&D expenses rose to $16 million from $7.9 million a year earlier, and the net loss widened to $18 million from $8 million. A Phase 3 trial in relapsed or refractory peripheral T-cell lymphoma will undergo a futility analysis around the first quarter of 2027 with no public data release. Corvus also invested another $5 million in China-based partner Angel Pharmaceuticals as part of a $13.5 million financing round, with Angel's first 24-patient cohort expected to finish enrolling in September. Hedge fund holders increased from 19 to 36, while short interest stands at 24.74% of the float.

A new report on the renal cancer pipeline for 2026 provides comprehensive insights into over 75 companies and more than 80 pipeline drugs. The analysis covers drug profiles across clinical and nonclinical stages, including assessments by product type, stage, route of administration, and molecule type. Key emerging drugs include Exelixis' zanzalintinib in phase III for non-clear cell renal cell carcinoma, Merck's quavonlimab combined with pembrolizumab in phase III, and Corvus Pharmaceuticals' ciforadenant in phase II. The report also details collaborations, acquisitions, and licensing activities, and highlights unmet needs and future perspectives in renal cancer therapeutics.

Corvus Pharmaceuticals director David Scott Moore acquired 21,700 common shares through an option exercise on June 11, 2026, according to an SEC filing. The transaction was valued at approximately $250,236 based on a weighted average purchase price of $11.53 per share. Following the purchase, Moore directly holds 21,700 shares worth about $252,000 at the June 11 closing price of $11.60, representing less than 0.03% of the company. He also received 15,000 stock options with an exercise price of $11.60 that vest in about a year. Corvus Pharmaceuticals, a clinical-stage immuno-oncology company, has seen its stock price rise 217% over the past year, with a market capitalization of $1.07 billion as of June 22, 2026.